Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

Tocilizumab Fails Late-Stage Trial for COVID-19

John Revill  |  July 29, 2020

ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…

Filed under:Drug Updates Tagged with:COVID-19Rochetocilizumab

Tocilizumab Fails to Help COVID-19 Patients in Italian Study

Emilio Parodi & Carl O'Donnell  |  June 23, 2020

(Reuters)—Roche’s rheumatoid arthritis drug Actemra (tocilizumab) failed to help patients with early-stage COVID-19 pneumonia in an Italian study, the latest instance in which an anti-inflammatory drug has fallen through in a coronavirus trial. Despite the setback, the Swiss drugmaker said that it is pressing ahead with testing tocilizumab in another trial against COVID-19, the disease…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19tocilizumab

Tocilizumab Begins Clinical Trial for COVID-19

Michele B. Kaufman, PharmD, BCGP  |  April 7, 2020

The FDA has authorized a phase 3 clinical trial examining the safety and efficacy of tocilizumab plus standard care in patients hospitalized with COVID-19…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19FDAsubcutaneous tocilizumabtocilizumabU.S. Food and Drug Administration (FDA)

China Approves Use of Tocilizumab for Coronavirus Patients

Reuters Staff  |  March 4, 2020

BEIJING (Reuters)—China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe conditions, health authorities said on Wednesday, as the country seeks to build up treatment regimens to help the infected recover. Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients…

Filed under:Drug Updates Tagged with:Chinacoronavirustocilizumab

Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector

Michele B. Kaufman, PharmD, BCGP  |  December 10, 2018

In a study, RA patients taking upadactinib monotherapy experienced less pain and morning joint stiffness than methotrexate-treated patients…

Filed under:Drug Updates Tagged with:ACTPenautoinjectorMethotrexatemonotherapyRheumatoid Arthritis (RA)tocilizumabupadacitinib

FDA Approves Subcutaneous Tocilizumab for Ages 2–17

Michele B. Kaufman, PharmD, BCGP  |  October 29, 2018

The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…

Filed under:ConditionsDrug UpdatesPediatric Conditions Tagged with:FDAPediatricsJIAsubcutaneous tocilizumabsystemic juvenile idiopathic arthritistocilizumabU.S. Food and Drug Administration (FDA)

Study Suggests Tocilizumab Monotherapy May Work for Some RA Patients

Mary Beth Nierengarten  |  October 18, 2018

For patients with rheumatoid arthritis (RA) who respond to subcutaneous tocilizumab, discontinuing methotrexate may be an option and offer an alternative to patients who cannot tolerate or prefer not to take methotrexate. “This is one of the first studies showing that methotrexate may be discontinued in a cohort of patients with a biologic agent without…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Methotrexatetocilizumab

Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis

Carina Stanton  |  August 17, 2018

For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al….

Filed under:ConditionsVasculitis Tagged with:ActemraTakayasu arteritis (TAK)tocilizumab

Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2018

New research has linked alendronate to reduced cardiovascular death in hip fracture patients…

Filed under:Drug Updates Tagged with:alendronatecardiovascularFDAFractureship fractureJuvenile Arthritis (JIA)polyarticular juvenile idiopathic arthritistocilizumabU.S. Food and Drug Administration (FDA)

E6011 & Tocilizumab Monotherapy Studies Show Promising Results for RA Patients

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2018

New RA Antibody Treatment SAN DIEGO—A recent study examined the pharmacokinetics, safety and efficacy of E6011, an anti-fractalkine monoclonal antibody designed to treat rheumatoid arthritis (RA).1 Researchers presented the results of this first 52-week trial of E6011 at the 2017 ACR/ARHP Annual Meeting in November. Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemo­taxis and adhesion…

Filed under:Drug UpdatesMeeting ReportsResearch Rheum Tagged with:ACR/ARHP Annual MeetingDrugsMethotrexateResearchRheumatoid arthritis

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences